Movement Alert｜BioNTech SE Rises 5.04% in Pre-Market Trading, Phase 3 Lung Cancer Trial Shows Statistically Significant Survival Benefit

Market Focus09-14 19:07

On September 14, BioNTech SE rose 5.04% in pre-market trading, trading at $101.4/share, with turnover of $1.1661 million.

The rally was driven by BioNTech SE and OncoC4 jointly releasing updated data from the first stage of the Phase 3 PRESERVE-003 clinical trial, which demonstrated a statistically significant overall survival benefit for candidate drug gotistobart in lung cancer patients, with survival nearly doubling. This positive readout provides critical support for the company's strategic pivot toward oncology.

Notably, BioNTech SE had faced significant headwinds in recent months. In late August, shares dropped roughly 9% after the company terminated a Phase 2 trial evaluating autogene cevumeran in colorectal cancer following an independent safety board recommendation. Additionally, Q2 earnings disappointed, with adjusted losses of 2.22 euros per share versus an expected loss of 1.99 euros, while revenue of 105.6 million euros missed the 157.8 million euro consensus. The company also cut its full-year revenue guidance to 1.60-1.90 billion euros from 2.00-2.30 billion euros. BMO Capital subsequently downgraded the stock to Market Perform with a reduced price target of $105.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment